Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Abstract

Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established. Our aim was to test the benefits of pravastatin treatment in an elderly cohort of men and women with, or at high risk of developing, cardiovascular disease and stroke. We did a randomised controlled trial in which we assigned 5804 men (n=2804) and women (n=3000) aged 70-82 years with a history of, or risk factors for, vascular disease to pravastatin (40 mg per day; n=2891) or placebo (n=2913). Baseline cholesterol concentrations ranged from 4.0 mmol/L to 9.0 mmol/L. Follow-up was 3.2 years on average and our primary endpoint was a composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Analysis was by intention-to-treat. Pravastatin lowered LDL cholesterol concentrations by 34% and reduced the incidence of the primary endpoint to 408 events compared with 473 on placebo (hazard ratio 0.85, 95% CI 0.74-0.97, p=0.014). Coronary heart disease death and non-fatal myocardial infarction risk was also reduced (0.81, 0.69-0.94, p=0.006). Stroke risk was unaffected (1.03, 0.81-1.31, p=0.8), but the hazard ratio for transient ischaemic attack was 0.75 (0.55-1.00, p=0.051). New cancer diagnoses were more frequent on pravastatin than on placebo (1.25, 1.04-1.51, p=0.020). However, incorporation of this finding in a meta-analysis of all pravastatin and all statin trials showed no overall increase in risk. Mortality from coronary disease fell by 24% (p=0.043) in the pravastatin group. Pravastatin had no significant effect on cognitive function or disability. Pravastatin given for 3 years reduced the risk of coronary disease in elderly individuals. PROSPER therefore extends to elderly individuals the treatment strategy currently used in middle aged people.

Keywords

PravastatinMedicineHazard ratioMyocardial infarctionInternal medicineStroke (engine)Clinical endpointPlaceboStatinRandomized controlled trialCardiologyCholesterolConfidence interval

MeSH Terms

AgedAged80 and overAnticholesteremic AgentsCholesterolLDLCoronary Artery DiseaseEndpoint DeterminationFemaleHumansMalePravastatinRisk Factors

Affiliated Institutions

Related Publications

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever , Björn Dahlöf , Neil R Poulter +11 more

The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol loweri...

2003 The Lancet 3773 citations

Reduction in Cardiovascular Events During Pravastatin Therapy

Robert P. Byington , J. Wouter Jukema , Jukka T. Salonen +5 more

Background It has been documented that the HMG coenzyme A reductase inhibitors, or statins, can decrease cardiovascular events and mortality in patients with clinical coronary d...

1995 Circulation 282 citations

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

Rory Collins , Jane Armitage , Sarah Parish +2 more

Individuals with diabetes are at increased risk of cardiovascular morbidity and mortality, although typically their plasma concentrations of LDL cholesterol are similar to those...

2003 The Lancet 2888 citations

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

Colin Baigent , Anthony Keech , Patricia M. Kearney +8 more

Results of previous randomised trials have shown that interventions that lower LDL cholesterol concentrations can significantly reduce the incidence of coronary heart disease (C...

2005 The Lancet 6760 citations

PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

J Ames S Hepherd , S Tuart M. C Obbe , I An F Ord +6 more

Background. Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of p...

1995 3460 citations

Publication Info

Year: 2002
Type: article
Volume: 360
Issue: 9346
Pages: 1623-1630
Citations: 3358
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3358

OpenAlex

104

Influential

2625

CrossRef

Cite This

APA Style

                            
                                
                                    James Shepherd, 
                                
                                    Gerard J. Blauw, 
                                
                                    Michael Murphy
                                
                                et al.
                            
                            (2002). 
                            Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. 
                            The Lancet
                            , 360
                            (9346)
                            , 1623-1630.
                            https://doi.org/10.1016/s0140-6736(02)11600-x
                        

Identifiers

DOI: 10.1016/s0140-6736(02)11600-x
PMID: 12457784

Data Quality

Data completeness: 81%